Rib-X Pharmaceuticals Files for I.P.O.

Rib-X Pharmaceuticals Inc., a New Haven, Conn.-based pharmaceutical developer, has filed plans for an initial public offering to raise up to $80 million. The company had previously raised capital from investors including Warburg Pincus, ABS Ventures, Axiom Ventures, EuclidSR Partners, MedImmune Ventures, Oxford Bioscience Partners and S.R. One. Deutsche Bank Securities will act as the sole book-running manager for the offering. William Blair & Company, Lazard Capital Markets and Needham & Co. will act as co-managers.

DealsNorth AmericaUSBriefs